Veru Shares Soar 88% on Novo Nordisk Partnership for Obesity Drug Trial
VERU sits 84% above its 52-week low of $2.05 on elevated volume (61× avg).
Summary
Veru Inc. has entered a clinical supply agreement with Novo Nordisk, securing free supply of Wegovy for its Phase 2b PLATEAU clinical trial of Enobosarm in obesity. This follows an 8-K filing yesterday, which triggered an 88% surge in Veru's stock. The collaboration with a major pharmaceutical company like Novo Nordisk provides significant validation for Veru's lead drug candidate and substantially reduces trial costs. Veru retains full development and commercialization rights, with Novo Nordisk holding a right of first negotiation for combination products. The ongoing Phase 2b PLATEAU trial results will be key for future development.
At the time of this announcement, VERU was trading at $3.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.9M. The 52-week trading range was $2.05 to $7.40. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: dpa-AFX.